Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 427 entries
View as:

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02155634 Org: User:
Start: 07/31/14 End: 03/31/21 Due: 03/31/22

ABI-008 Trial in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00531271 Org: User:
Start: 11/01/07 End: 12/01/08 Due: 12/01/09

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01733875 Org: User:
Start: 11/01/12 End: 10/09/13 Due: 10/09/14

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00388960 Org: User:
Start: 11/01/06 End: 12/01/10 Due: 12/01/11

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Phase: N/A Priority: Normal
NCT ID: NCT02921828 Org: User:
Start: 04/30/15 End: 12/10/15 Due: 12/10/16

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01975610 Org: User:
Start: 10/31/13 End: 02/29/16 Due: 02/28/17

AVIDA The Vidaza® (Azacitidine) Patient Registry

Phase: N/A Priority: Normal
NCT ID: NCT00481273 Org: User:
Start: 10/31/06 End: 08/31/10 Due: 08/31/11

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04434196 Org: User:
Start: 12/21/20 End: 05/21/24 Due: 05/21/25

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04211545 Org: User:
Start: 10/21/19 End: 12/26/19 Due: 12/26/20

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Phase: N/A Priority: Normal
NCT ID: NCT00057616 Org: User:
Start: 10/01/02 End: 07/15/05 Due: 07/15/06

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00477529 Org: User:
Start: 04/01/07 End: 06/02/11 Due: 06/02/12

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT02124850 Org: User:
Start: 10/28/14 End: 10/31/16 Due: 10/31/17

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02807454 Org: User:
Start: 07/07/16 End: 01/03/22 Due: 01/03/23

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT01881230 Org: User:
Start: 09/26/13 End: 10/28/16 Due: 10/28/17

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Phase: N/A Priority: Normal
NCT ID: NCT02921802 Org: User:
Start: 07/20/10 End: 03/29/13 Due: 03/29/14

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00056160 Org: User:
Start: 01/01/03 End: 10/01/08 Due: 10/01/09

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02313012 Org: User:
Start: 01/05/15 End: 05/03/16 Due: 05/03/17

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM

Phase: N/A Priority: Normal
NCT ID: NCT04730505 Org: User:
Start: 02/04/21 End: 06/21/21 Due: 06/21/22

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT01999582 Org: User:
Start: 11/30/13 End: 08/31/16 Due: 08/31/17

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03601078 Org: User:
Start: 12/13/18 End: 10/15/25 Due: 10/15/26

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Phase: N/A Priority: Normal
NCT ID: NCT03340662 Org: User:
Start: 11/09/17 End: 01/27/18 Due: 01/27/19

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

Phase: N/A Priority: Normal
NCT ID: NCT01964430 Org: User:
Start: 03/28/14 End: 06/30/22 Due: 06/30/23

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT06318676 Org: User:
Start: 03/21/24 End: 11/15/24 Due: 11/15/25

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02343536 Org: User:
Start: 04/29/15 End: 01/29/20 Due: 01/29/21

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01666444 Org: User:
Start: 10/31/12 End: 07/31/16 Due: 07/31/17